Advertisement
Home Tags Cancer: Misc.

Tag: Cancer: Misc.

The American Society for Radiation Oncology, Sept. 24-27

The 59th Annual Meeting of the American Society for Radiation Oncology The annual meeting of the American Society for Radiation Oncology...
Patients with rheumatoid arthritis and venous thromboembolism have increased risk of cancer in the first year after VTE and during a longer follow-up period

Cancer Risk Up for RA Patients With Venous Thromboembolism

Risk of cancer increased during the first year after VTE and in longer follow-up period
Children with inflammatory bowel disease face an increased risk of cancer that persists into adulthood

Childhood-Onset IBD May Raise Risk of Cancer

Researchers think chronic inflammation in gastrointestinal tract may be driving force
The first biosimilar drug to treat cancer has been approved by the U.S. Food and Drug Administration.

FDA Approves First Biosimilar Drug for Cancer

Mvasi (bevacizumab-awwb) is biosimilar to Avastin
Mutational signatures could more accurately identify mismatch repair-deficiency than sequencing of MMR genes

Mutational Signatures Can More Accurately ID MMR Deficiency

Mutational signatures better report mismatch repair deficiency than sequencing of MMR genes
β2-adrenergic receptor signaling in host immune cells regulates CD8+ T-cell frequency and functional orientation within the tumor microenvironment

β-Adrenergic Receptor Signaling Affects Tumor Microenvironment

Reducing signaling facilitates conversion of tumors to immunologically active microenvironment in mice
The age-adjusted U.S. cancer death rate decreased 25 percent from 1991 to 2014

AACR Releases 2017 Cancer Progress Report

Twenty-five percent decrease in age-adjusted U.S. cancer death rate from 1991 to 2014
Neurological complications associated with anti-programmed death 1 antibody treatment have a diverse phenotype

Diverse Neurological Effects Linked to Anti-PD-1 Therapy

Complications seen after median of 5.5 cycles of anti-PD-1-inhibitors; include myopathy, neuropathies
The median cost of cancer drug development is $648.0 million

Median Cost of Cancer Drug Development $648.0 Million

Total revenue from sales of 10 drugs was $67.0 billion, with total R&D spending of $7.2 billion
Injection of inactivated modified vaccinia virus Ankara into tumors is effective and generates antitumor immunity

Inactivated Vaccinia Virus Shows Promise Against Advanced Cancer

Combined with immune checkpoint blockade therapy, iMVA generates synergistic antitumor effects